Rifamycin in Minimal Hepatic Encephalopathy
Rifamycin in Minimal Hepatic Encephalopathy
This is a randomized double-blind placebo-controlled trial of MHE in patients with cirrhosis
 using rifamycin SV-MMX 600mg BID vs placebo for 30 days with PK, safety, microbiota, brain
 function and brain MRI endpoints.
Hepatic encephalopathy (HE) is a highly prevalent neuro-cognitive complication of cirrhosis
 characterized by cognitive dysfunction, and high rate of subsequent mortality and recurrence.
 HE also places a tremendous burden with a relentless increase in inpatient stay duration with
 charges topping $7244.7 million in 20092. There were almost 23,000 hospitalizations for HE in
 2009 and far more patients with HE who are being managed as an outpatient in the US. In the
 NACSELD (North American Consortium for the Study of End-Stage Liver Disease) experience, HE
 in inpatients is an independent risk factor for mortality and the leading cause of
 readmissions in patients with cirrhosis.

 HE has two major phases, covert or minimal HE (MHE), which is only recognized by specialized
 tests and overt HE (OHE), which is clinically obvious. OHE forms the tip of the iceberg,
 while MHE affects as many as 60% of tested patients with cirrhosis.

 MHE is associated with changes in specific cognitive domains that result in altered
 health-related quality of life and daily function. This can promote the development of OHE,
 impair driving and employment, increase falls and is independently associated with a risk of
 hospitalizations and mortality.

 There is an alteration of gut microbial composition and function (bile acid changes,
 endotoxemia and gut metabolic products) in cirrhosis, which worsens with disease progression
 with MHE and OHE. Current treatments for OHE are mostly focused on the gut, including
 lactulose and rifaximin. However, despite extracting a major toll on disease progression,
 there is no current guideline to treat MHE. Prior studies using lactulose and rifaximin have
 been performed in this setting with improvement in brain function, brain MRI changes and
 microbial function. However, these are still not standard of care.

 Rifamycin SV MMX® 200 mg is a gut-specific antibiotic with a long track record of safety that
 has been FDA approved for the treatment of traveler's diarrhea. Unlike rifaximin,
 rifamycin-SV MMX mostly affects the colon, where the bacterial load is much larger than in
 the other parts of the GI tract. The impact of rifamycin on MHE has not been studied to date.
 This is a randomized double-blind placebo-controlled trial of MHE in patients with cirrhosis.
Inclusion Criteria:

 1. Age 18-75 years

 2. Cirrhosis defined by any one of the following

 1. Cirrhosis on liver biopsy or transient elastography

 2. Nodular liver on imaging

 3. Endoscopic or radiological evidence of varices in a patient with chronic liver
 disease

 4. Platelet count <150,000/mm3 and AST/ALT ratio >1 in a patient with chronic liver
 disease

 3. Women of childbearing age will need to be on accepted birth control for 10 days prior
 to entering study and 30 days after the end of the last dose of the study drug.

 4. Cognitive impairment on PHES aggregate score [more than or greater than] -4SD - based
 on norms published in Allampati et al located at the website www.encephalapp.com17
 (This is the accepted diagnosis of minimal HE.)

 5. Willing and able to participate, provide samples and complete follow-up

 6. Stable Liver function tests between 2-12 weeks prior to enrollment (can include the
 screening laboratory values details in exclusion criteria)

 Exclusion Criteria:

 1. Unclear diagnosis of cirrhosis (does not meet the criteria outlined above)

 2. Child score >8

 3. Increasing trend of ALT and AST in the 2-12 weeks prior to study inclusion (Baseline
 values established by at least two samples obtained at least 2 weeks and no more than
 8-12 weeks apart) to account for disease related changes in liver enzymes and
 bilirubin while on study that may otherwise be inappropriately attributed to study
 drug. >20% increase in baseline serum AST, ALT, ALP and total bilirubin (TBL) will be
 considered an exclusion criterion.

 4. Unable to consent, follow for the study duration

 5. Normal performance on PHES

 6. Mini-mental status exam<2518

 7. Recent alcohol abuse (within 3 months)

 8. Recent illicit drug abuse (within 3 months) except marijuana

 9. Current use of psychoactive drugs apart from long-standing opioids or stable
 anti-depressant use.

 10. Prior overt HE episodes defined as West-Haven Criteria grade 2 or higher in the past
 that required hospitalization or initiation of lactulose or rifaximin therapy

 11. Currently on lactulose or rifaximin

 12. Current or recent invasive bacterial or fungal infections (<1 month)

 13. Allergic reactions to rifamycin, rifampin or rifaximin

 14. MELD >20

 15. TIPS placement

 16. Serum sodium<125

 17. On SBP prophylaxis

 18. Post-transplant cirrhosis

 19. Infections within 4 weeks

 20. End-stage organ failures: CHF with EF<25%, End-stage renal disease on dialysis, COPD
 on home oxygen

 21. Pregnancy (positive urine pregnancy test at screening)

 22. Current on statin therapy

 23. In the opinion of the PI, those who are unlikely to survive or remain without liver
 transplant for 6 weeks, or cannot adhere to the trial activities.